User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

3811

Interactions with Platform & by Email *

INTERACTIONS

686

Unique # Participated *

PARTICIPANTS

114

Responses Validated *

VALIDATIONS

33

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Epigenetics: An Introduction.....II-1
Cancer: The Key Focus Area for Epigenetics.....II-1
Histone Changes as Biomarkers: An Emerging Field.....II-1
1$100
   Future of Epigenetics.....II-21$100
   Scope of Epigenetics.....II-3
Oncology.....II-3
Psychiatry.....II-3
1$100
   Outlook of Epigenetic Treatments.....II-4
Current and Future Analysis.....II-4
Market Segmentation.....II-4
Therapeutics.....II-4
1$100
   Diagnostics.....II-5
Research Tools.....II-5
Epigenetics Stretching to hESC Research.....II-5
Epigenetics: Transforming from Special Niche to Widespread Collection of Tools.....II-5
1$100
   Pros and Cons of First Generation Epigenetics Drugs.....II-6
Advances in Epigenetics Technologies, Therapeutics and Diagnostics.....II-6
1$100
   Outlook for Product Positioning and Innovation.....II-7
Epigenetic Community Initiatives.....II-7
Patent Law in Japan.....II-7
2$125
   Epigenomics Pioneers the Epigenetics Diagnostics.....II-9
Merck Leads HDAC Inhibitors Market.....II-9
Huge Potential for Novel Therapies.....II-9
Combination Therapy.....II-9
1$100
   Novel Technologies.....II-101$100
   Epigenetics - Definition.....II-11
Categories of Signals in Epigenetics.....II-11
Introduction.....II-11
1$100
   Etymology and Meaning.....II-12
Epigenetics - Molecular Base.....II-12
1$100
   Mechanisms.....II-13
Chromatin Remodeling and DNA Methylation.....II-13
2$125
   RNA Transcripts and Programmed Proteins.....II-15
Prions.....II-15
1$100
   Structural Inheritance Systems.....II-16
Functions and Outcomes.....II-16
Development.....II-16
Medicine.....II-16
Evolution.....II-16
1$100
   Epigenetics in Microorganisms.....II-171$100
   Epigentek Group Launches New Measures for DNA Methylation Shifts.....II-18
QIAGEN Introduces EpiTect® HRM™ PCR Kit.....II-18
Enzo Biochem Rolls Out Wide-Ranging Epigenetics Tools.....II-18
1$100
   Applied Biosystems Unveils Novel Small RNA Expression Analysis Solution.....II-19
Sigma-Aldrich Launches Imprint™ Methylated DNA Quantification Kit.....II-19
1$100
   Sigma-Aldrich Unveils ChIP Kit for Epigenetic Research.....II-20
Pyrosequencing Introduces New PyroMark™ Q24.....II-20
Qiagen Expands Epitect Portfolio.....II-20
1$100
   Applied Biosystems Introduces New SOLiD™ 3 System.....II-211$100
   Merck Merges with Schering-Plough.....II-22
Celldex Therapeutics Acquires CuraGen.....II-22
NCCN Upgrades Vidaza to Category 1.....II-22
PrognosDx Health Obtains UCLA Epigenetics Technology Rights.....II-22
1$100
   PROGEN Posts Positive Results from Preclinical Epigenetics Product.....II-23
Pharmacyclics Announces Positive Scientific Results from PCI-24781 Clinical Trial
  Targeting HDAC.....II-23
CellCentric Signs Agreement with Takeda.....II-23
1$100
   Orion Genomics and Novartis Ink Multi-Year Collaboration and License Agreement.....II-24
SuperGen Collaborates with GlaxoSmithKline.....II-24
QIAGEN to Acquire SABiosciences.....II-24
1$100
   QIAGEN Takes Over DxS.....II-25
CellCentric Expands Number of Researchers.....II-25
Roche NimbleGen Enters into Collaboration with Sigma-Aldrich.....II-25
Quest Diagnostics Gains biomarker license from Epigenomics.....II-25
1$100
   Babraham Institute Launches New Epigenomics Sequencing Facility.....II-26
Active Motif Enters into Licensing Agreement with City of Hope.....II-26
NIH to Grant US$62 Million for Epigenetic Research.....II-26
1$100
   Rush University Medical Center Obtains US$5.5 Million Grant from NIH.....II-27
Celgene Takes Over Pharmion.....II-27
Eisai Takes Over MGI PHARMA.....II-27
Affymetrix Acquires Panomics.....II-27
1$100
   QIAGEN Takes Over Biotage’s Biosystems.....II-28
Millipore Corporation and Agilent Technologies Collaborate.....II-28
Invitrogen Signs License Agreement with Genisphere.....II-28
1$100
   Invitrogen and IMBcom Proprietary Ink Licensing Agreement.....II-29
OncoMethylome Sciences and QIAGEN Sign Licensing Agreement.....II-29
Pharmacyclics Characterizes Highly Selective HDAC Inhibitor.....II-29
Celgene’s Vidaza Gains Approval for MDS and AML in Europe.....II-29
1$100
   Medistem Enters into Epigenetics Collaboration.....II-30
Orion Geomics Obtains License for IGF2 Gene from Johns Hopkins.....II-30
Progen Pharmaceuticals Acquires CellGate.....II-30
BioServe Purchases Genomics Collaborative.....II-30
1$100
   Sigma-Aldrich and Epigentek Signs Licensing Agreement.....II-31
Constellation Pharmaceuticals and BioTrove Enter into R&D Collaboration.....II-31
1$100
   Salk Institute Researchers Present Full Epigenome Map.....II-32
Baylor College of Medicine Recognizes Epigenetic Affects on Obesity.....II-32
Prenatal Starvation Could Cause Epigenetic Modifications.....II-32
John Hopkins Scientists Reveal Epigenetic Modifications Take Place Over
  Lifetime.....II-32
Advances in Epigentic Regulation Focuses on Breast Cancer.....II-32
1$100
   Celgene Corporation (US).....II-33
CellCentric Ltd. (UK).....II-33
Epigenomics AG (Germany).....II-33
Epigentek Group, Inc. (US).....II-33
1$100
   Genpathway, Inc. (US).....II-34
Merck & Co., Inc. (US).....II-34
MGI Pharma, Inc. (US).....II-34
Millipore Corporation (US).....II-34
1$100
   OncoMethylome Sciences S.A (Belgium).....II-35
Orion Genomics (US).....II-35
1$100
   Table 1: World Recent Past, Current & Future Analysis for Epigenetics by Application Area - Drug Discovery, Diagnostics and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-361$350
   Table 2: World 10-Year Perspective for Epigenetics by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery, Diagnostics, and Others Markets for Years 2006, 2009, & 2015 (includes corresponding Graph/Chart).....II-371$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com